MODAG GmbH   Report issue

For profit Phase 1
Founded: Wendelsheim Germany (2013)

Organization Overview

First Clinical Trial
2019
NCT04208152
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

MODAG GmbH

Active Ingredients

Drugs in Phase 1 Trials (2)

anle138b (3 trials)

fluvoxamine (luvox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Parkinson Disease (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2